OMERS ADMINISTRATION Corp Makes New Investment in Alpha Teknova, Inc. (NASDAQ:TKNO)

OMERS ADMINISTRATION Corp purchased a new position in shares of Alpha Teknova, Inc. (NASDAQ:TKNO) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 40,100 shares of the company’s stock, valued at approximately $335,000. OMERS ADMINISTRATION Corp owned about 0.08% of Alpha Teknova as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. increased its position in shares of Alpha Teknova by 622.5% during the 4th quarter. JPMorgan Chase & Co. now owns 4,400 shares of the company’s stock worth $37,000 after purchasing an additional 3,791 shares during the last quarter. Mount Lucas Management LP acquired a new position in shares of Alpha Teknova during the 4th quarter worth approximately $75,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Alpha Teknova during the 4th quarter worth approximately $94,000. NewEdge Advisors LLC increased its position in shares of Alpha Teknova by 14.3% during the 4th quarter. NewEdge Advisors LLC now owns 15,632 shares of the company’s stock worth $131,000 after purchasing an additional 1,953 shares during the last quarter. Finally, Barclays PLC acquired a new position in shares of Alpha Teknova during the 4th quarter worth approximately $132,000. Institutional investors and hedge funds own 13.81% of the company’s stock.

Alpha Teknova Stock Down 1.1%

TKNO stock opened at $6.54 on Tuesday. The company has a current ratio of 4.73, a quick ratio of 3.94 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $349.50 million, a PE ratio of -8.84 and a beta of 0.50. Alpha Teknova, Inc. has a 1-year low of $1.16 and a 1-year high of $10.37. The business’s 50 day simple moving average is $5.87 and its 200 day simple moving average is $7.10.

Alpha Teknova (NASDAQ:TKNO) last posted its earnings results on Thursday, May 8th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. The business had revenue of $9.60 million for the quarter, compared to analyst estimates of $9.41 million. Alpha Teknova had a negative return on equity of 35.30% and a negative net margin of 87.17%. As a group, research analysts anticipate that Alpha Teknova, Inc. will post -0.58 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum started coverage on Alpha Teknova in a report on Monday, February 10th. They set a “buy” rating and a $12.00 target price on the stock.

Alpha Teknova Company Profile

Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.